Merck details injectable Keytruda data as it awaits autumn FDA decision

Merck details injectable Keytruda data as it awaits autumn FDA decision

Merck shared Phase 3 data showing that an injectable version of its blockbuster cancer drug Keytruda is comparable to the approved intravenous infusion in lung cancer patients. And it said it's seeking approval of the injectable for a broad range of cancers.

A new treatment for lung cancer involving the combination of two drugs reduced the chances of death from a type of disease in a metastatic or advanced phase affecting mainly women and non-smokers by 25%. The side effects, however, are greater and more toxic. Read more (03/27/2025)

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting

Reqorsa® Immunogene Therapy is a Potential Therapy for Ras Inhibitor Resistant Non-Small Cell Lung Cancer